- Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and impacts approximately six per 100,000 individuals in North America and Europe.
- Current treatments are inadequate because they only address a small segment of the Duchenne muscular dystrophy population, leaving a huge unmet need.
- CAPR is potentially positioned to address the Duchenne muscular dystrophy space due to its uniqueness as a universal therapeutic that is potent and well tolerated.
For further details see:
Capricor Therapeutics - Shockingly Undervalued With Imminent Catalysts In Play